Lithium carbonate and affective disorders. V: A double-blind study of prophylaxis of depression in bipolar illness.

Abstract

The efficacy of lithium carbonate as a prophylactic drug against depression in bipolar manic depressive patients was assessed through a double-blind, placebo-controlled study of patients who had histories of recurrent depressions and hypomanias ("bipolar II"). The results revealed that treatment with lithium carbonate resulted in a reduction in the frequency of depressive attacks was observed with lithium carbonate treatment during the study (mean length of study, approximately 16 months), although there was a suggestion that the depressive attacks that occurred during treatment with lithium carbonate might be less severe than with placebo treatment.

• Authors: D L Dunner, F Stallone, R R Fieve
• Journal: Archives of general psychiatry (Arch Gen Psychiatry) Vol. 33 Issue 1 Pg. 117-20 (Jan 1976) ISSN: 0003-990X [Print] United States
• PMID: 1108832 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Placebos
• Lithium

Topics

• Adult
• Bipolar Disorder (prevention & control)
• Clinical Trials as Topic
• Depression (epidemiology, prevention & control)
• Female
• Humans
• Lithium (therapeutic use)
• Male
• Middle Aged
• Placebos
• Recurrence
• Time Factors